Tradipitant for Motion Sickness: Expanding the Therapeutic Landscape of NK₁ Receptor Antagonists
Erin St Onge1, Adonice Khoury2
1Department of Pharmacy Education and Practice, University of Florida College of Pharmacy, Orlando, USA.
Objective:
To review the efficacy, safety, and tolerability of tradipitant for the prevention of vomiting induced by motion.
Data Sources:
A literature search was conducted through PubMed using the following terms: tradipitant, motion sickness, Nereus, and neurokinin-1 (NK-1) receptor antagonist.
Study Selection And Data Extraction:
Articles describing the pharmacology, pharmacokinetics, efficacy, safety, and/or tolerability of tradipitant were included in this review.
Data Synthesis:
Tradipitant is a NK-1 receptor antagonist shown to reduce vomiting due to motion. Clinical trials have demonstrated improvements in the occurrence of vomiting as well as multiple episodes of vomiting secondary to various sea conditions. Common adverse effects associated with this agent include fatigue, somnolence, and headache when taken as a single-dose treatment.
Conclusions:
Scopolamine and first-generation antihistamines are commonly used to prevent and treat motion sickness; however, their use is limited by their significant adverse effect profiles. Tradipitant, the newest agent approved for motion sickness, provides clinicians with an additional treatment option for this common condition.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

